GEN Exclusives

More »

GEN News Highlights

More »
Jun 2, 2010

NCI to Conduct Phase I Study with Immatics' Glioblastoma Vaccine

  • NCI’s Center for Cancer Research (CCR) is to sponsor and carry out a Phase I trial evaluating immatics biotechnologies’ IMA950 therapeutic vaccine candidate for glioblastoma. Immatics will collaborate with CCR and will supply the drug and carry out immunomonitoring of treated patients.

    The clinical trials agreement will involve a Phase I evaluation of IMA950 in stable or recurrence-free glioblastoma patients following standard radiochemotherapy using temozolomide.

    The deal complements immatics’ existing IMA950 collaboration with Cancer Research UK, which was announced in February. Cancer Research UK agreed to sponsor and conduct a Phase I trial in newly diagnosed glioblastoma patients, to evaluate combined treatment using IMA950 and radiochemotherapy.

    IMA950 has been developed using immatics’ Xpresident antigen discovery platform. The vaccine comprises 11 tumor-associated peptides (TUMAPs) selected on the basis of their overexpression in tumor versus healthy tissue, their immunogenicity, and their relevance to tumor function.

    Immatics is focused on the development of what it terms rationally designed therapeutic cancer vaccines. Lead product, IMA901, is composed of a combination of TUMAPs for the treatment of renal cell carcinoma and is undergoing Phase II trials in Europe. A colorectal carcinoma candidate, IMA910, is being evaluated in a Phase I/II study.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »